Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$16.79|
|52 Week High||US$11.81|
|52 Week Low||US$28.20|
|1 Month Change||23.91%|
|3 Month Change||1.27%|
|1 Year Change||25.16%|
|3 Year Change||-60.12%|
|5 Year Change||-23.02%|
|Change since IPO||39.92%|
Recent News & Updates
Atara Biotherapeutics: One More Time
We take our second look at Atara Biotherapeutics and update our investment thesis to account for recent events. The company has a full slate of milestones over the next year including a rolling BLA submission. A full investment analysis and recommendation follows in the paragraphs below.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Could Be 46% Below Their Intrinsic Value Estimate
Does the August share price for Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) reflect what it's really worth? Today, we...
|ATRA||US Biotechs||US Market|
Return vs Industry: ATRA matched the US Biotechs industry which returned 26.1% over the past year.
Return vs Market: ATRA underperformed the US Market which returned 31.5% over the past year.
Stable Share Price: ATRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ATRA's weekly volatility (6%) has been stable over the past year.
About the Company
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis.
Atara Biotherapeutics Fundamentals Summary
|ATRA fundamental statistics|
Is ATRA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ATRA income statement (TTM)|
|Cost of Revenue||US$13.32m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-3.63|
|Net Profit Margin||-4,281.64%|
How did ATRA perform over the long term?See historical performance and comparison
Is Atara Biotherapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ATRA ($16.79) is trading below our estimate of fair value ($41.18)
Significantly Below Fair Value: ATRA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ATRA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ATRA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ATRA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ATRA is overvalued based on its PB Ratio (4.3x) compared to the US Biotechs industry average (3.2x).
How is Atara Biotherapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ATRA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ATRA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ATRA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ATRA's revenue (69.3% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: ATRA's revenue (69.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ATRA is forecast to be unprofitable in 3 years.
How has Atara Biotherapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ATRA is currently unprofitable.
Growing Profit Margin: ATRA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ATRA is unprofitable, and losses have increased over the past 5 years at a rate of 29.3% per year.
Accelerating Growth: Unable to compare ATRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: ATRA has a negative Return on Equity (-95.85%), as it is currently unprofitable.
How is Atara Biotherapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ATRA's short term assets ($392.3M) exceed its short term liabilities ($88.8M).
Long Term Liabilities: ATRA's short term assets ($392.3M) exceed its long term liabilities ($36.4M).
Debt to Equity History and Analysis
Debt Level: ATRA is debt free.
Reducing Debt: ATRA had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ATRA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ATRA has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 27.8% each year.
What is Atara Biotherapeutics's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ATRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ATRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ATRA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ATRA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ATRA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Pascal Touchon (58 yo)
Dr. Pascal Touchon, D.V.M., has been President, Chief Executive Officer and Director at Atara Biotherapeutics, Inc. since June 24, 2019. He serves as Director of Cogen Therapeutics, Inc. since August 2018....
CEO Compensation Analysis
Compensation vs Market: Pascal's total compensation ($USD5.29M) is above average for companies of similar size in the US market ($USD3.70M).
Compensation vs Earnings: Pascal's compensation has been consistent with company performance over the past year.
Experienced Management: ATRA's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Experienced Board: ATRA's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.1%.
Atara Biotherapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Atara Biotherapeutics, Inc.
- Ticker: ATRA
- Exchange: NasdaqGS
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.423b
- Shares outstanding: 84.76m
- Website: https://www.atarabio.com
Number of Employees
- Atara Biotherapeutics, Inc.
- 611 Gateway Boulevard
- Suite 900
- South San Francisco
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/22 22:43|
|End of Day Share Price||2021/09/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.